Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Invested Capital (2016 - 2023)

Rapid Therapeutic Science Laboratories' Invested Capital history spans 8 years, with the latest figure at -$2.7 million for Q2 2023.

  • For Q2 2023, Invested Capital fell 44.57% year-over-year to -$2.7 million; the TTM value through Jun 2023 reached -$2.7 million, down 44.57%, while the annual FY2022 figure was -$3.1 million, 124.41% down from the prior year.
  • Invested Capital for Q2 2023 was -$2.7 million at Rapid Therapeutic Science Laboratories, up from -$2.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $979557.0 in Q3 2021 and bottomed at -$3.2 million in Q1 2019.
  • The 5-year median for Invested Capital is -$1.6 million (2021), against an average of -$1.5 million.
  • The largest YoY upside for Invested Capital was 298.12% in 2021 against a maximum downside of 4403.33% in 2021.
  • A 5-year view of Invested Capital shows it stood at -$607949.0 in 2019, then surged by 105.28% to $32109.0 in 2020, then crashed by 4403.33% to -$1.4 million in 2021, then crashed by 124.41% to -$3.1 million in 2022, then grew by 13.39% to -$2.7 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Invested Capital are -$2.7 million (Q2 2023), -$2.7 million (Q1 2023), and -$3.1 million (Q4 2022).